Paramount promised 30 movies a year to win Warner Bros. Losing Miramax if it fails may not scare it

A federal judge approved Paramount Skydance's settlement with 12 states, removing the final legal barrier to its nearly $111 billion acquisition of Warner Bros. Discovery; the companies expect to close on Oct. 6. The consent decree requires at least 30 theatrical releases annually in 2027-28 and 32 annually from 2029-31, backed by $30 million penalties for each uncured film shortfall and a potential divestiture of Paramount's 49% Miramax stake. The combined company must also spend at least $300 million more annually on U.S. production than the companies spent in 2025, or $1.5 billion over five years. Paramount also named Mattel CEO Ynon Kreiz as co-CEO alongside David Ellison, while critics argue the settlement's enforcement mechanisms are too weak.

Analysis

Closing removes the remaining event-risk discount, but PSKY/WBD holders are now underwriting integration execution rather than regulatory optionality. The production commitments are economically more binding than the asset-divestiture provision: a marginal wide release can consume materially more than the per-film penalty once marketing, distribution and working-capital losses are included. Management therefore has an incentive to meet the quota through lower-budget, co-financed releases and to concentrate capital behind franchise titles, limiting the near-term uplift to studio EBITDA.

The structural beneficiary is theatrical exhibition, not necessarily the merged studio. A mandated slate of wide releases plus a protected exclusive window improves screen utilization and concession traffic for CNK, AMC and IMAX, while the larger release calendar raises competition for premium-format screens and marketing inventory. Conversely, DIS faces a modest increase in family/franchise release-date congestion, although its scale and owned IP make the effect more likely to pressure industry marketing returns than Disney's revenue base.

The consensus may overstate the remedy's constraint on post-merger cost cutting. The delayed measurement period, cure mechanics and ability to seek modification make this a 2027-29 issue, while the apparent penalty is likely cheaper than funding uneconomic films; a weak box-office environment could make deliberate penalties rational. The more investable 1-3 month catalysts are synergy guidance, debt/refinancing disclosures, leadership responsibilities and any revised theatrical slate. Mattel's loss of Ynon Kreiz's full attention is an underappreciated near-term governance overhang; any value from deeper toy-to-film collaboration remains unquantified.

Key Decisions for Investors

• Do not add to PSKY/WBD solely on closing de-risking; reassess after first combined-company guidance. Require a credible synergy run-rate, leverage path and film-capex bridge before underwriting upside. Thesis is falsified by EBITDA guidance relying on aggressive content cuts or refinancing at materially wider spreads.
• Initiate a 6-12 month long CNK or IMAX basket versus a short PSKY/WBD basket only on post-close strength: exhibitors gain from higher mandated theatrical supply while the studio absorbs production and P&A commitments. Target 15-20% relative return; exit if the 2027 slate shifts toward acquired titles/limited releases or domestic box office weakens materially.
• Treat MAT as a watch-list short/underweight into management-transition clarity rather than a film-IP long. Escalate only if Kreiz's successor process, retention package or guidance indicates disruption to toy execution; cover if Mattel demonstrates incremental licensed-film economics without reducing core product margins.
• Set alerts for combined-company net leverage, annual content cash spend and announced 2027 wide-release count. A production-spend increase funded by debt, or fewer than roughly 20 credible wide releases, would support a bearish PSKY/WBD view over the next 6-18 months.